Irish medical technology firm Medtronic has received approval from the US Food and Drug Administration (FDA) for its MiniMed Connect, which offers convenient access to personal diabetes data.


The company has designed MiniMed to provide a mobile connection to critical information for managing diabetes, allowing people with diabetes to discreetly and conveniently view their insulin pump and continuous glucose monitor (CGM) data on a smartphone.

Medtronic diabetes services and solutions vice-president and general manager Annette Brüls said: "Engagement from people with diabetes, loved ones and healthcare providers is key to living well with diabetes.

"With MiniMed Connect, the entire care team can have access to critical diabetes data to inform the decisions that help people have better outcomes."

MiniMed Connect includes a small device that easily fits on a key chain or in a pocket, a smartphone app for the person with diabetes, and a web display on desktop or mobile devices for their care partners.

The device securely transfers pump and sensor glucose data from the patient’s MiniMed insulin pump to the app and web display, which shows real-time sensor glucose and insulin information on the phone or any Internet-enabled device anytime and anywhere.

In addition, the system offers healthcare teams with more comprehensive data and convenient access to their patients’ diabetes data.

The MiniMed Connect remote web display is said to be available with iOS, Android, or any other Internet-enabled devices.

Image: Medtronic operational headquarters, Minneapolis. Photo: courtesy of Medtronic, Inc.